Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
seizures
Biotech
Bright Minds seizure study on partial hold over toxicity in mice
The FDA put a partial hold on the seizure study application over preclinical toxicity data and concerns about its preparations for enrolling children.
Nick Paul Taylor
Nov 2, 2026 8:43am
Praxis pauses one of its seizure programs after phase 2 fail
Jun 2, 2026 5:23am
Xenon epilepsy candidate 'blows away' ph. 3 expectations
Mar 9, 2026 10:55am
Bright Minds anti-seizure candidate shines in phase 2 win
Jan 6, 2026 10:38am
Praxis sees success in ph. 2 seizure trial, setting up FDA push
Dec 5, 2025 10:00am
Ceribell nets FDA nod for detecting seizures in preterm newborns
Nov 26, 2025 9:49am